Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries.
Alan G Wade, Gordon M Crawford, David Young...
https://pubmed.ncbi.nlm.nih.gov/31353997/Actively Recruiting
Led by University of the Pacific · Updated on 2024-12-11
90
Participants Needed
1
Research Sites
12 weeks
Total Duration
Researchers are evaluating the effectiveness of topical 2.5% hydrocortisone compared to topical 1% diclofenac in treating temporomandibular joint TMJ arthralgia, which is pain in the jaw joint. The study aims to answer how these treatments compare in reducing pain, improving jaw function, and causing side effects. This is a randomized, phase 3 clinical trial sponsored by the University of the Pacific. Participants will apply either hydrocortisone 2.5% cream or diclofenac 1% cream to the affected TMJ area four times a day for 21 days. On the first day, participants will be examined, and their pain levels and jaw function limitations recorded. They will continue applying the cream for three weeks, with periodic reminders to maintain adherence. On day 21, participants will report their pain, jaw function, compliance, and any side effects experienced. During the study, researchers will collect data through questionnaires and monitor participant adherence with reminders by email and phone calls. Data will be anonymized and analyzed to compare the treatments effects on pain intensity, jaw function limitation, and side effects. The main outcomes are pain and jaw function changes measured on days 1 and 21, with side effects reported on day 21. Participants are involved for a total of 21 days of treatment and follow-up.
CONDITIONS
Topical Treatment for TMJ Arthralgia
A
Andrew Young, DDS, MSD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of the Pacific
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Hydrocortisone 2.5% topical (applied to TMJ four times daily) | Diclofenac 1% topical (applied to TMJ four times daily) |
|---|---|---|
| What it is | A topical corticosteroid gel at 2.5% strength, applied directly to the jaw joint four times daily. Investigated to reduce inflammation and pain in TMJ arthralgia. | A topical nonsteroidal anti-inflammatory (NSAID) gel at 1% strength, applied to the jaw joint four times daily. Used to relieve pain and reduce inflammation in TMJ arthralgia. |
| Role in trial | Serves as the experimental treatment arm, compared for pain reduction and jaw function improvement against diclofenac topical. | Serves as the active comparator arm within the randomized trial, benchmarked for pain and jaw function outcomes. |
| Primary use | Intended for reducing pain and inflammation in TMJ arthralgia through local corticosteroid action. | Intended for relieving joint pain and inflammation in TMJ arthralgia through local NSAID activity. |
| How it is given or performed | Applied as a gel directly over the affected TMJ four times daily for 21 days. | Applied as a gel over the affected TMJ four times daily for 21 days. |
| Evidence status | No published clinical results are available yet for hydrocortisone topical treatment in TMJ arthralgia; ongoing trial will establish efficacy. | There is moderate external evidence supporting topical diclofenac for musculoskeletal pain, including positive findings for osteoarthritis. Its efficacy in TMJ pain is under investigation, but studies support pain relief in similar joint conditions. |
| Important limitations | Hydrocortisone's use for TMJ pain is investigational and lacks direct published outcome evidence; typical risks may include skin irritation and potential systemic steroid effects if overused. | External evidence supports diclofenac topical for musculoskeletal pain, but evidence for TMJ-specific outcomes is limited. Risks may include localized skin reactions and rare systemic absorption effects. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 21 days
Participants apply either 2.5% hydrocortisone cream or 1% diclofenac cream four times daily to the affected temporomandibular joint for arthralgia.
1 baseline visit and 1 follow-up visit on day 21
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alan G Wade, Gordon M Crawford, David Young...
https://pubmed.ncbi.nlm.nih.gov/31353997/Fritz U Niethard, Morris S Gold, Gail S Solomon...
https://pubmed.ncbi.nlm.nih.gov/16331769/Frédérique Bariguian Revel, Marina Fayet, Martina Hagen
https://pubmed.ncbi.nlm.nih.gov/32086778/University of the Pacific
Lead Sponsor